These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34161657)

  • 1. Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China.
    Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Yang S; Gui L; Sun Y; Shi Y
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e87-e95. PubMed ID: 34161657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan.
    Mitsui T; Mori T; Fujita N; Inada H; Horibe K; Tsurusawa M;
    Pediatr Blood Cancer; 2009 May; 52(5):591-5. PubMed ID: 19156862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
    Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
    Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
    Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
    Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
    Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
    Thomas DA; Kantarjian H; Smith TL; Koller C; Cortes J; O'Brien S; Giles FJ; Gajewski J; Pierce S; Keating MJ
    Cancer; 1999 Oct; 86(7):1216-30. PubMed ID: 10506707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults.
    Mitsui T; Fujita N; Koga Y; Fukano R; Osumi T; Hama A; Koh K; Kakuda H; Inoue M; Fukuda T; Yabe H; Takita J; Shimada A; Hashii Y; Sato A; Atsuta Y; Kanda Y; Suzumiya J; Kobayashi R
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28129. PubMed ID: 31876367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma].
    Wang P; Li CX; Zhang Y; Chen J; Chen XC; Yang D; Zhou J; Zong XP; Yang Z; Wu M; Yang MZ; Song YQ; Zhu J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):198-203. PubMed ID: 32311888
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia.
    Martino R; Bellido M; Brunet S; Sureda A; Peyret M; Guárdia R; Altés A; Domingo-Albós A; Sierra J
    Bone Marrow Transplant; 1998 May; 21(10):1023-7. PubMed ID: 9632276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
    Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
    Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma].
    Xu T; Chen J; Jin ZM; Miao M; Fu CC; Qiu HY; Tang XW; Han Y; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):656-60. PubMed ID: 27587245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.
    Ribera JM; Morgades M; Genescà E; Chapchap EC; Montesinos P; Acuña-Cruz E; Gil C; García-Cadenas I; Barba P; González-Campos J; Queipo de Llano MP; Torrent A; Ribera J; Granada I; Bernal T; Díaz-Beyá M; Amigo ML; Coll R; Tormo M; Vall-Llovera F; Gómez-Centurión I; Sánchez-Sánchez MJ; Soria B; Cladera A; Artola MT; Garcia-Guiñon A; Giménez-Conca A; Amador ML; Martínez-Sánchez P; Algarra JL; Vidal MJ; Alonso N; Maluquer C; Llorente L; García-Boyero R; Ciudad J; Feliu E; Orfao A;
    Hematol Oncol; 2021 Oct; 39(4):529-538. PubMed ID: 34405901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.